AbbVie (NYSE:ABBV) Stock Jumps 1.6% – Should You Buy?

AbbVie Inc. (NYSE:ABBV) shares were up 1.6% during mid-day trading on Monday. The stock traded as high as $281.30 and last traded at $280.8740. 5,493,473 shares changed hands during trading, a decline of 14% from the average daily volume of 6,414,131 shares. The stock had previously closed at $276.47.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi and Rinvoq remain the primary growth engines. Analysts expect the two drugs to drive third-quarter revenue growth and offset continuing erosion in Humira sales. However, increasing competition in immunology remains a consideration. Will Skyrizi & Rinvoq Drive AbbVie’s Top-Line Growth in Q3?
• Positive Sentiment: New clinical data support AbbVie’s leading immunology portfolio. The company highlighted long-term SKYRIZI and RINVOQ findings at ACG 2026, reinforcing confidence in the drugs’ durability and commercial potential. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026
• Positive Sentiment: Analyst sentiment is supportive. Guggenheim reaffirmed a “Buy” rating, while a separate report noted that AbbVie’s accelerating growth, recent acquisition and fresh FDA approval could support its next major revenue opportunity. Wall Street’s cited targets range from a $246 bearish case to a $297 bullish case. AbbVie Stock Rating Reaffirmed as Buy by Guggenheim
• Neutral Sentiment: Sector M&A activity is improving. Rising pharmaceutical deal activity is supporting broader biotechnology sentiment as drugmakers seek replacement products ahead of patent expirations, though this is an industry tailwind rather than a specific new catalyst for ABBV. Biotech’s Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
• Negative Sentiment: Valuation and income concerns could limit upside. ABBV’s strong share-price appreciation has pushed its dividend yield to its lowest level since 2018, while its elevated valuation leaves the stock sensitive to slower-than-expected Skyrizi and Rinvoq growth, Humira erosion or additional competition.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ABBV shares. Bank of America reiterated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Leerink Partners boosted their price target on shares of AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Argus upped their price objective on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. HSBC increased their price objective on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and increased their price objective for the company from $235.00 to $300.00 in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $277.18.

AbbVie Price Performance

The stock has a 50 day simple moving average of $259.06 and a two-hundred day simple moving average of $236.86. The company has a market cap of $496.25 billion, a price-to-earnings ratio of 79.34, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the prior year, the business earned $2.97 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts forecast that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. AbbVie’s payout ratio is presently 195.48%.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

A number of institutional investors have recently bought and sold shares of the company. Burk Holdings LLC purchased a new position in shares of AbbVie during the 2nd quarter worth $30,000. Marquette Asset Management LLC increased its position in shares of AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the last quarter. Abound Financial LLC acquired a new stake in shares of AbbVie during the 4th quarter worth about $32,000. Principia Wealth Advisory LLC raised its holdings in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Merkkuri Wealth Advisors LLC purchased a new stake in AbbVie in the 1st quarter valued at about $34,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.